# HER2-specific Chimeric Antigen Receptor (CAR) T Cells for Children With Ependymoma

> **NCT04903080** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Children's Oncology Group** · enrollment: 50 (estimated)

## Conditions studied

- Ependymoma

## Interventions

- **BIOLOGICAL:** HER2 Specific CAR T Cell

## Key facts

- **NCT ID:** NCT04903080
- **Lead sponsor:** Children's Oncology Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-07-27
- **Primary completion:** 2026-03-31
- **Final completion:** 2043-07-20
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2026-04-06

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04903080

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04903080, "HER2-specific Chimeric Antigen Receptor (CAR) T Cells for Children With Ependymoma". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04903080. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*